Back to search results

Online Pain Education for Crohn's Disease and Ulcerative Colitis

This study is looking at two online programs, "Empowered Relief" and "Living Better with Chronic Pain," to see if they can help adults with Crohn's disease or ulcerative colitis (types of inflammatory bowel disease or IBD) who experience ongoing pain. Both programs teach skills to manage pain and take about 2 hours to complete online. Researchers want to see if these programs reduce pain interference (how much pain affects daily life) over 8 weeks. You might be able to join if you have a confirmed diagnosis of Crohn's disease or ulcerative colitis, have had chronic pain related to your IBD for at least 3 months, and meet certain pain severity and medical stability requirements. The study aims to enroll 60 participants.

Study design
This is a pilot randomized controlled trial, meaning participants will be randomly assigned to one of the two online programs. The study plans to enroll 60 participants.
What's involved
You would complete one 2-hour online program on your personal device. You would also complete online surveys at the beginning of the study and then weekly for 8 weeks after completing the program.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 8 weeks after completing the online program, with weekly surveys.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07671313

Online Pain Education for Crohn's Disease and Ulcerative Colitis

Not Yet Recruiting
NAAges 18+InterventionalTreatment
Cedars-Sinai Medical Center
~60 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:Empowered ReliefLiving Better with Chronic Pain

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PROMIS Pain Interference
Measured over Baseline, then weekly post-treatment (Weeks 1-8)

Conditions

Crohn's Disease
Ulcerative Colitis (UC)
Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)

Explore related trials

Crohn DiseaseUlcerative Colitis

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Christopher V Almario, MD, MSHPM · PRINCIPAL_INVESTIGATOR · Cedars-Sinai Medical Center

Who to contact

Zoe Krut, MSHS
[email protected]
310-423-0699
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Physician-confirmed diagnosis of Crohn's disease or ulcerative colitis
Chronic pain (visceral and/or somatic) related to IBD for at least 3 months
NIH PROMIS Pain Interference scale T-score ≥60
Medically stable, defined as:
Able to understand and complete questionnaires independently in English
Access to an internet-enabled device for online surveys and intervention access.

Exclusion

Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation
Current use of standing opioid medications, given the often severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia
Prior participation in cognitive behavioral therapy (CBT) specifically targeting chronic IBD-related pain

What this trial measures

  • PROMIS Pain InterferenceBaseline, then weekly post-treatment (Weeks 1-8)

    Pain interference as measured by the validated 8-item PROMIS Pain Interference (PROMIS-PI) scale. It assesses self-reported consequences of pain on relevant aspects of one's life, including the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. This instrument is universal, rather than disease-specific. The recall period for this scale is 7 days.